Kerschan-Schindl, K. http://orcid.org/0000-0002-1128-7532
Hackl, M.
Boschitsch, E.
Föger-Samwald, U.
Nägele, O.
Skalicky, S.
Weigl, M.
Grillari, J.
Pietschmann, P.
Funding for this research was provided by:
Austria Wirtschaftsservice (No. P1405046-SZL01)
Medical University of Vienna
Article History
Received: 10 November 2020
Accepted: 17 December 2020
First Online: 11 January 2021
Compliance with Ethical Standards
:
: M. Hackl reports personal fees and other from TAmiRNA GmbH, outside the submitted work; in addition, Dr. Hackl has a patent EP14198560.6: J. Grillari, S. Weilner, M. Hackl, R. Grillari, E. Schraml, compositions and methods for the treatment of osteoporosis issued. S. Skalicky and M. Weigl report personal fees from TAmiRNA, outside the submitted work. J. Grillari reports other from TAmiRNA GmbH, outside the submitted work; in addition, Dr. R. Grillari has a patent EP14198560: J. Grillari, S. Weilner, M. Hackl, R. Grillari, E. Schraml, compositions and methods for the treatment of osteoporosis pending. P. Pietschmann reports grants from Amgen GmbH, personal fees from Biomedica Medizinprodukte, personal fees from BE Perfect Eagle, grants and personal fees from Fresenius Kabi GmbH, personal fees from Medahead GmbH, personal fees from Mylan GmbH, personal fees from UCB Pharma, other from TAmiRNA, outside the submitted work. The other authors declare no competing interest.
: The study was approved by the ethical committee of the Medical University of Vienna (Approval Number 1463/2014). It was conducted in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
: Participants have consented to the publication of their data in aggregated form.